Photodynamic therapy in primary breast cancer: the first human study (Conference Presentation)

Shramana M. Banerjee; Soha El Sheikh; Anmol Malhotra; Sandy Mosse; Sweta Parker; Norman Williams; Sandy MacRobert; Rifat Hamoudi; Stephen G. Bown; Mo R. S. Keshtgar

doi:10.1117/12.2525480

14 August 2019 Photodynamic therapy in primary breast cancer: the first human study (Conference Presentation)

Shramana M. Banerjee, Soha El Sheikh, Anmol Malhotra, Sandy Mosse, Sweta Parker, Norman Williams, Sandy MacRobert, Rifat Hamoudi, Stephen G. Bown, Mo R. S. Keshtgar

Author Affiliations +

Proceedings Volume 11070, 17th International Photodynamic Association World Congress; 1107055 (2019) https://doi.org/10.1117/12.2525480
Event: 17th International Photodynamic Association World Congress, 2019, Cambridge, Massachusetts, United States

Abstract

Primary breast cancer while increasing in incidence has been successfully treated with a combination of surgery and adjuvant therapies in the majority of patients. Novel treatments for primary breast cancer need to show additional benefits to existing treatments with equivalent or improved efficacy for niche groups. Photodynamic therapy (PDT) is a potential novel treatment and a Phase I/IIA, open label, non-randomised, single site trial of photodynamic therapy for the treatment of primary breast cancer was conducted. The primary aim was to identify the light dose required for 12 mm of tumour necrosis (or a plateau of necrosis) assessed by histopathology. Post-dose MRI correlation with histopathology findings in treated tumours and in normal breast tissue was sought. In addition adverse events were recorded and comparison of outcome made with matched controls. Results of the first human clinical trial with 12 patients with median follow-up of 39 months showed PDT was well tolerated, with no adverse effects and comparable outcome to control populations. Tumour necrosis increased with incremental increases in light dose, however some patients showed a poor response even at the highest light dose. Analysis suggests that there may be predictive factors for good and poor response. PDT in primary breast cancer requires further investigation to identify which patients would most benefit from this therapy.

Conference Presentation

Citation Download Citation

Shramana M. Banerjee, Soha El Sheikh, Anmol Malhotra, Sandy Mosse, Sweta Parker, Norman Williams, Sandy MacRobert, Rifat Hamoudi, Stephen G. Bown, and Mo R. S. Keshtgar "Photodynamic therapy in primary breast cancer: the first human study (Conference Presentation)", Proc. SPIE 11070, 17th International Photodynamic Association World Congress, 1107055 (14 August 2019); https://doi.org/10.1117/12.2525480

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
PRESENTATION

WATCH
PRESENTATION SAVE TO MY LIBRARY

GET CITATION

KEYWORDS

Photodynamic therapy

Breast cancer

Control systems

Therapeutics

Breast

Clinical trials

Magnetic resonance imaging

Show All Keywords

Keywords/Phrases

Search In:

Publication Years